 |
|||
        
|
Apjohn Ventures Fund is a new venture capital firm based in Kalamazoo, Michigan established to invest primarily in early stage life sciences companies across the Midwest. The goal of the Fund is to provide investors with superior financial returns by making equity investments in innovative life sciences companies with sustainable and outstanding growth potential.
We take our name, Apjohn, from the original family name of one of our founders. The use of this family name reflects our desire to inspire life sciences entrepreneurs to build pharmaceutical successes much like Dr. William E. Upjohn did at the turn of the last century. We welcome you to our web site and invite you to learn more about Apjohn Ventures. |
8.13.2018 7.15.2015 ProNAi Therapeutics Announces Pricing of Initial Public Offering 5.27.2014 12.9.2013 11.7.2013 ProNAi to Present Phase II Clinical Data at ASH for PNT2258, a BCL2 Targeted Drug 3.19.2013 BioMarin to Advance BMN-701 for Pompe Disease to Next Phase (2/3) of Development 11.9.2012 5.15.2012 Svelte Medical Systems Announces Final Patient Treated in the DIRECT Drug-Eluting Stent Study 3.15.2012 Smarticles Extend Their Reach In ProNAi’s DNAi Approach 1.4.2012 CytoPherx Raises $34 Million to Move Into U.S. Clinical Trials 11.9.2011 Svelte Medical Systems Offers All-In-One Drug-Eluting Stent Application 8.17.2010 BioMarin Acquires ZyStor Therapeutics, Inc. 6.28.2010 Upsher-Smith Laboratories Adds ITI-111 (Nasal Midazolam) to CNS Development Pipeline 10.7.2005
|
 |
 |